DK0880970T3 - Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose - Google Patents

Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose

Info

Publication number
DK0880970T3
DK0880970T3 DK98104718T DK98104718T DK0880970T3 DK 0880970 T3 DK0880970 T3 DK 0880970T3 DK 98104718 T DK98104718 T DK 98104718T DK 98104718 T DK98104718 T DK 98104718T DK 0880970 T3 DK0880970 T3 DK 0880970T3
Authority
DK
Denmark
Prior art keywords
treatment
anticytokine
pharmaceutical compositions
disseminated sclerosis
disseminated
Prior art date
Application number
DK98104718T
Other languages
English (en)
Inventor
David Wallach
Dan Aderka
Hartmut Engelmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0880970(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0880970T3 publication Critical patent/DK0880970T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK98104718T 1991-05-07 1992-05-07 Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose DK0880970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne
EP92107685A EP0512528B1 (en) 1991-05-07 1992-05-07 Pharmaceutical compositions comprising an anticytokine

Publications (1)

Publication Number Publication Date
DK0880970T3 true DK0880970T3 (da) 2006-11-20

Family

ID=11062415

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98104718T DK0880970T3 (da) 1991-05-07 1992-05-07 Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
DK92107685T DK0512528T3 (da) 1991-05-07 1992-05-07 Farmaceutisk præparat omfattende et cytokin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK92107685T DK0512528T3 (da) 1991-05-07 1992-05-07 Farmaceutisk præparat omfattende et cytokin

Country Status (12)

Country Link
EP (2) EP0880970B1 (da)
JP (1) JP3320774B2 (da)
AT (2) ATE334695T1 (da)
AU (1) AU1609492A (da)
CA (1) CA2068027C (da)
DE (2) DE69229975T2 (da)
DK (2) DK0880970T3 (da)
ES (2) ES2270479T3 (da)
GR (1) GR3031805T3 (da)
IL (1) IL98078A0 (da)
PT (1) PT880970E (da)
ZA (1) ZA923310B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2153384T3 (es) * 1993-07-30 2001-03-01 Kennedy Inst Of Rheumatology Metodo para tratar la esclerosis multiple.
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
DK0839046T3 (da) 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
PT1471974E (pt) * 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
CA2032191C (en) * 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
ATE190629T1 (de) * 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE69229975T2 (de) 2000-05-11
DE69229975D1 (de) 1999-10-21
EP0512528B1 (en) 1999-09-15
DE69233643D1 (de) 2006-09-14
JPH05170661A (ja) 1993-07-09
ZA923310B (en) 1993-01-27
EP0512528A2 (en) 1992-11-11
GR3031805T3 (en) 2000-02-29
CA2068027A1 (en) 1992-11-08
DK0512528T3 (da) 1999-12-20
CA2068027C (en) 2003-09-23
ES2137935T3 (es) 2000-01-01
IL98078A0 (en) 1992-06-21
AU1609492A (en) 1992-11-12
EP0880970A1 (en) 1998-12-02
EP0512528A3 (en) 1993-07-21
JP3320774B2 (ja) 2002-09-03
ES2270479T3 (es) 2007-04-01
PT880970E (pt) 2006-12-29
ATE184488T1 (de) 1999-10-15
EP0880970B1 (en) 2006-08-02
ATE334695T1 (de) 2006-08-15
DE69233643T2 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
NO943617D0 (no) Fusjonsproteiner omfattende tumornekrosefaktor-reseptor
EA200000311A1 (ru) Новый белок иммунной системы - кау
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
DK1042305T3 (da) Inhibering af p38-kinase ved anvendelse af symmetriske og asymmetriske diphenylurinstoffer
DK442788A (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
NL990033I2 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met degelijk DNA.
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE69332955T2 (de) Chimäre prokoagulierende Proteine
DE69533359D1 (de) Veränderte menschliche c3-proteine
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
DE69803392D1 (de) Anti-cd40l immunotoxine zur behandlung von krankheiten
NO950420D0 (no) Interferon endelse derav
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
DE69002383D1 (de) Zusammensetzung zur heilung von autoimmunkrankheiten.
DE69002821D1 (de) Zusammensetzung zur haarbehandlung.
TH30275A (th) โปรตีนดัดแปลง